Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erbach – page 7

675 clinical trials in Erbach, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erbach at a glance
675
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

675 trials in Erbach

Open in trial search

Efficacy and safety of votoplam in adults with Huntington’s disease: a randomized, double‑blind, placebo‑controlled Phase 3 trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Votoplam
  • Sponsor:Novartis Pharma AG

Colorectal cancer+2

Recruiting

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.

Efficacy and Safety of SIL204 Combined with Standard Chemotherapy in Patients with Locally Advanced Pancreatic Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:SIL204
  • Sponsor:Silexion Therapeutics Ltd.

A Phase 2a Study Evaluating the Efficacy and Safety of MK-8690 in Adults with Moderately to Severely Active Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MK-8690
  • Sponsor:Merck Sharp & Dohme LLC

Safety and Tolerability of Intrathecal TRCN-1023 in Adults with Amyotrophic Lateral Sclerosis (ALS) – Randomized Placebo‑Controlled Phase 1/2 Trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:TRCN-1023
  • Sponsor:Trace Neuroscience Inc.

Epcoritamab for Adults with Relapsed or Refractory Marginal Zone Lymphoma: A Phase II Open‑Label Study

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Universitaetsklinikum Ulm AöR

Switch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Gruppo Oncologico Del Nord Ovest

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901
  • Sponsor:AstraZeneca AB

Colitis ulcerative+2

Recruiting

Study of ly4395089 and mirikizumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY4395089
  • Sponsor:Eli Lilly & Co.

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Safety and efficacy of autologous CD34+ cells transduced with a vector encoding human NCF1 in children and adults with p47‑deficient chronic granulomatous disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH A LENTIVIRAL VECTOR ENCODING THE HUMAN NCF1 GENE
  • Sponsor:Somagenetix AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erbach

What the registry says about research in the country

01 Alzheimer's Disease Research

Groundbreaking clinical trials focusing on early Alzheimer's disease treatments and interventions for associated psychosis. Studies are evaluating novel compounds for managing cognitive decline and neuropsychiatric symptoms.

  • Early-stage disease intervention
  • Psychosis management
  • Cognitive function preservation

Multiple therapeutic approaches targeting both cognitive symptoms and behavioral manifestations of the disease.

02 Migraine Studies

Innovative research examining new treatments for menstrual migraine and chronic migraine conditions. Comparative studies evaluating the effectiveness of different preventive treatments.

  • Preventive treatment protocols
  • Medication comparison studies
  • Gender-specific approaches

Focus on developing targeted therapies for specific types of migraines and their prevention.

03 Multiple Sclerosis Initiatives

Comprehensive research programs investigating treatments for various forms of multiple sclerosis, including progressive and relapsing forms. Studies utilize advanced imaging techniques to track disease progression.

  • Progressive MS treatments
  • Brain atrophy assessment
  • Disability progression prevention

Advanced therapeutic approaches targeting different disease manifestations and progression patterns.

04 Parkinson's Disease Studies

Innovative research focusing on early-onset Parkinson's disease, examining long-term treatment efficacy and brain pathophysiology changes. Studies aim to understand disease progression and therapeutic interventions.

  • Early intervention strategies
  • Long-term treatment effects
  • Disease modification approaches

Emphasis on understanding disease mechanisms and developing targeted therapeutic solutions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.